Trends in kaposi’s sarcoma morbidity: A retrospective cohort study of heart and lung transplant recipients

Tal Serlin, Tuvia Ben Gal, Mordechai R. Kramer, Diana Sorin, Emmilia Hodak, Batya Davidovici*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Data on post-transplant Kaposi’s sarcoma in heart and lung transplant recipients are sparse. This study exa-mined the incidence of biopsy-proven post-transplant Kaposi’s sarcoma in thoracic organ recipients over a period of 20 years. As mammalian target of rapamycin inhibitors were introduced in 2006 as optional maintenance immunosuppressive therapy, the overall results were analysed and stratified into 2 groups: 1996 to 2005 and 2006 to 2016. A total of 867 transplant recipients met the study criteria. Post-transplant Kaposi’s sarcoma was diagnosed in 7 (0.81%) patients. Five cases (0.19% of transplant recipients) were recorded in 1996 to 2005 and 2 (0.03% of transplant recipients) in 2006 to 2016 (p = 0.04). Multivariable logistic regression analyses identified the following as risk fac-tors: period of transplantation (odds ratio (OR) 4.844, 95% confidence interval (95% CI) 1.156–20.291), age at transplantation (OR 1.066, 95% CI 0.992–1.145), and North African origin (OR 7.282, 95% CI 12.55– 42.254). This study found a decreased incidence of post-transplant Kaposi’s sarcoma over the last 20 years, mainly attributed to the change in immunosup-pressive therapy.

Original languageEnglish
Article numberadv00528
JournalActa Dermato-Venereologica
Issue number8
StatePublished - 2021


  • Epidemiology
  • Heart transplant recipients
  • Immunosuppressive maintenance thera-py
  • Kaposi’s sarcoma
  • Lung transplant recipients
  • Mammalian target of rapamycin inhibitors


Dive into the research topics of 'Trends in kaposi’s sarcoma morbidity: A retrospective cohort study of heart and lung transplant recipients'. Together they form a unique fingerprint.

Cite this